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COMPARING POTENTIAL STRATEGIES TO ELIMINATING MEDICARE 
PART D’S COVERAGE GAP
Zhang Y
University of Pittsburgh, Pittsburgh, PA, USA
OBJECTIVES: Eliminating the Medicare’s coverage gap is on health reform’s agenda. 
This study compares the implications of current House and Senate bills on closing the 
donut hole as well as use of generic drugs on three outcomes: 1) proportion of beneﬁ-
ciaries entering and going through the gap, 2) duration in the gap, and 3) total and 
out-of-pocket annual pharmacy spending. METHODS: 2007 pharmacy data of a 
random sample of beneﬁciaries enrolled in a Medicare-Advantage Part D plan were 
used to evaluate these outcomes under three proposals: 1) reducing the size of the 
donut hole by $500 (Senate bill); 2) reducing the size of the donut hole by $500 and 
a 50% discount for brand-names used in the donut hole (House bill); and 3) switching 
to generic drugs after several brand-names go off-patent by end-2011. RESULTS: 
Under 2007 Part D, 20% beneﬁciaries entered the gap and 3.5% entered the cata-
strophic period. People stayed in the gap for 132 days; their total pharmacy spending 
was $4561, with $2337 out-of-pocket and $2224 by Medicare. Under the Senate bill, 
14% would enter and 3.5% would go through the gap. Those entering the gap would 
stay there for 120 days and their total pharmacy spending would be $5214, $2788 
out-of-pocket and $2426 by Medicare. The House bill would save additional $791 
among beneﬁciaries entering the gap. Several blockbusters including Lipitor, Zyprexa, 
Prevacid, Novasc, Aricept will go off-patents by end-2011. If patients switched to their 
generic counterparts, 17% would enter the gap and 1.8% would enter the catastrophic 
period. The average gap duration would be 128 days. People entering the gap would 
spend $4476 total, $2115 out-of-pocket and $2361 by Medicare. CONCLUSIONS: 
Reducing the gap size can delay entering the gap, but may not reduce beneﬁciaries’ 
out-of-pocket spending. A strategy combining it with generic use could be more 
effective.
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BENEFICIARY CHOICE IN MEDICARE PART D
King AJ
University of Arkansas for Medical Sciences, Little Rock, AR, USA
OBJECTIVES: To empirically assess the preferences of Medicare beneﬁciaries in their 
selection of an approved Part D prescription drug plan. METHODS: A descriptive 
analysis illustrated the tendencies of those Part D beneﬁciaries who independently 
chose their 2007 Part D plan to keep their previous drug coverage and to consider 
other available Part D plans. The ﬁnal study sample included the 2007 Internet survey 
respondents who (by October 2007) were at least 65 years old and insured through 
Medicare Part D and excluded the Part D beneﬁciaries automatically enrolled in a 
Part D plan. This study was cross-sectional, using 2007 Internet Survey data from the 
Health and Retirement Study. A logistic regression model measured the collective 
explanatory power of a set of six variables describing beneﬁciary formulary prefer-
ences, a variable describing beneﬁciary plan knowledge, and a set of three demo-
graphic variables in determining beneﬁciaries’ choice to keep their prior Part D drug 
plan. The outcome and explanatory variables, except for two demographic variable 
representing respondent wealth and age, were coded as binary. RESULTS: Due to 
missing values, a total of 74 part D beneﬁciaries were included in this study. Of the 
Part D beneﬁciaries who independently chose their 2007 plan coverage, 82.8% kept 
their same coverage in 2007 as in 2006 and 71.9% looked at other available formulary 
plans. The likelihood ratio chi-square score of 21.38 (p < 0.0186) showed our logistic 
regression model to be statistically signiﬁcant. 2007 Part D beneﬁciaries with clear 
preferences for insurance company reputation and plans with gap coverage were 83.84 
(p < 0.019) and 0.03 (p < 0.041) times as likely to hold onto their 2006 coverage. 
CONCLUSIONS: In order to assess the efﬁciency of the Part D program, it is impor-
tant to understand the important factors surrounding beneﬁciary choice.
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COST CONSEQUENCE ANALYSIS OF PRESCRIPTION DRUG LABEL 
CHANGES
Zargarzadeh AH, Law AV
Western University of Health Sciences, Pomona, CA, USA
OBJECTIVES: According to a mandate, all California pharmacies will be changing 
to a new “patient centered “prescription label beginning January 2011. An increase 
in label size may be needed to comply with possible additional information/format 
changes that are being considered. This cost consequence study explored the impact 
of label changes to California pharmacies and projected to all US pharmacies. 
METHODS: A cost model was built based on input from 3 experts. It included: 1) 
continuing costs: bottle, cap or closure, label (dual web sheet paper vs. thermal roll, 
paper used, glue used), and 2) One-time costs: software program, additional storage 
area and staff training. Average additional costs for increasing bottle size from 13 
dram to 30 dram, increasing label size and added adhesive was estimated to be 10.5 
cents. A literature search conducted to estimate consequence of label change identiﬁed 
only two articles that addressed the impact of a new commercial label on health 
outcomes and medication safety. RESULTS: The additional costs to pharmacies for 
the new label would be close to $34 million ($372M for US) assuming 324 million 
prescriptions are ﬁlled by retail and mail order pharmacies annually in California (3.54 
billion for US). On average, each of 6000 California pharmacies will incur additional 
costs of $5700 dollars each year. Software changes were assumed to be zero cost. 
Additional storage and employee training were dealt with differently by each phar-
macy hence were used as parameters for a sensitivity analysis. The two studies on 
consequence did not show any signiﬁcant difference in impact on outcomes between 
using the new label and a traditional label. CONCLUSIONS: Additional costs of label 
change per pharmacy may not be considered signiﬁcant; however these costs could be 
transferred to patients as pharmacies are already experiencing ﬁnancial constraints.
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THE RELATIONSHIP OF RESEARCH AND DEVELOPMENT ACTIVITY 
WITH U.S. MEDICAL DRUG SHORTAGES
Stino M, McGhan WF
University of the Sciences in Philadelphia, Philadelphia, PA, USA
OBJECTIVES: In an earlier study, we explored the characteristics of the medical drugs 
and devices in short supply on or before June 1, 2009. In this study, we looked at the 
internal characteristics of the individual manufacturers for those drugs. In addition, 
we examined the possible association for ﬁrms with signiﬁcant research and develop-
ment (R&D) operations and the number and average length of shortages. METHODS: 
We assembled an expert panel to determine the R&D status of these ﬁrms based on 
whether or not their primary mission was to develop novel drugs. We conducted 
statistical analyses to test several null hypotheses: 1) that there is no association 
between a ﬁrm’s R&D activity and the number of drugs in short supply for which it 
is listed; 2) that there is no association between a ﬁrm’s R&D activity and the average 
length of its shortages; 3) that there is no difference between ﬁrms with signiﬁcant 
R&D operations and other ﬁrms in regard to the number of shortages for which they 
are listed; and 4) that there is no difference between ﬁrms with signiﬁcant R&D 
operations and other ﬁrms in regard to the average duration of their shortages. 
RESULTS: We failed to reject the null hypotheses for overall, active, and resolved 
shortages, except in one case. We found that there was no signiﬁcance in most of these 
associations except in the relationship between a ﬁrm’s R&D status and the length of 
its resolved shortages. CONCLUSIONS: Based on this data, these results suggest that 
ﬁrms classiﬁed as being research-intensive did not have signiﬁcantly more drugs in 
short supply or longer durations for current and overall shortages. Firms focused on 
R&D had longer resolved shortages. We intend to continue investigating other manu-
facturer characteristics and their possible association with shortages.
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MEDICARE PART D AND ITS IMPACT ON PRESCRIPTION DRUG USE
Khan N1, Kaestner R2
1University of New Mexico Health Sciences Center, Albuquerque, NM, USA, 2University of 
Illinois at Chicago, Chicago, IL, USA
OBJECTIVES: Signiﬁcant fraction (approximately 30%) of elderly were without 
prescription drug coverage prior to Medicare Part D. Medicare Part D provided a 
subsidized prescription drug beneﬁt to all elderly beneﬁciaries. The objective of this 
study is to estimate the impact of part D on prescription drug utilization. METHODS: 
The analysis uses 2000–2006 Medicare Current Beneﬁciary Survey (MCBS). MCBS is 
nationally representative survey of elderly and disabled individuals. The survey con-
tains detailed information on prescription drug coverage, prescription drug utilization, 
and other sociodemographic, economic variables. The sample was limited to those age 
65–85 years with complete year of data, either uninsured or who had private coverage. 
Prescription drug coverage was calculated for each month, if respondent had coverage 
for at least 6-months they were assumed to be privately insured. We estimate the 
likelihood of being uninsured using pre Medicare part D data from 2000–2003. We 
then compared changes in prescription utilization pre- to post Medicare Part D for 
those more and less likely to be uninsured prior to Part D. RESULTS: In year 2005, 
approximately 30% of our sample did not have any prescription drug coverage. After 
part D was introduced, only 10% of the sample report not having any prescription 
drug coverage. On an average, total number of prescription used increased by 5 from 
2005–2006. Part D also included discount cards which were introduced in June 2004. 
The results indicated that discount cards increased the number of prescriptions by 3. 
Therefore, total impact of part D was approximately 8 more prescriptions. These 
results were supported in multivariate models (p = 0.01) controlling for various 
demographic and economic factors. CONCLUSIONS: Medicare part D increased 
prescription drug use signiﬁcantly among elderly non-Medicaid population. Future 
analysis should assess the impact of part D on health care utilization and health.
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ACCESS WITH EVIDENCE DEVELOPMENT SCHEMES: A FRAMEWORK 
FOR THEIR DESIGN AND EVALUATION
Staﬁnski T1, McCabe C2, Menon D1
1University of Alberta, Edmonton, AB, Canada, 2University of Leeds, Leeds, West Yorkshire, 
UK
OBJECTIVES: In recent years, efforts to balance access to promising, new technologies 
with the need to ensure effective and efﬁcient use of limited health care resources have 
focussed on the adoption of various forms of conditional coverage arrangements, 
collectively referred to as Access with Evidence Development (AED) schemes. While 
such arrangements continue to attract interest, concerns over ‘value for money’ have 
also been raised, since they often require considerable, committed resources for imple-
mentation. This project aimed to develop a framework for guiding the design of future 
AED schemes and apply this framework to the evaluation of existing AED schemes. 
METHODS: An international workshop involving researchers and decision-makers 
with experience designing and implementing AED schemes was held. Presentations 
comprising case studies from Australia, Canada, the UK, and the US were used to 
highlight issues/challenges and lessons learnt. They were followed by discussions 
around the strengths/weaknesses and resource requirements of such schemes. Based 
